Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : EntreMed (ENMD) -- Ignore unavailable to you. Want to Upgrade?

To: biodoc who wrote (1002)	5/14/1998 2:19:00 PM
From: Andreas Helke	Read Replies (1) \| Respond to of 2135

Deals between pharma and and biotech companies mostly include equity investments as part of the mix. If EntreMed can keep its stock price up thanks to the interest of the general investing public then the higher stock price will result in less dilution. The same logic applies to secondary offerings. They need to offer less shares to begin with and have a better chance that the secondary is received well and therefore does not depress the stock price. Andreas